Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6.

Ellen M ApperlooDavid Z I CherneyAnja Birk KuhlmanJohannes F E MannSøren RasmussenEllen Burgess Katherine R TuttleBlaz VrhnjakHiddo J Lambers Heerspink

Published in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024)

A clinically meaningful reduction in risk of chronic kidney disease progression was observed with semaglutide versus placebo regardless of HbA1c, BP, BMI, and UACR levels.

Keyphrases

body weight
blood pressure
body mass index
heart rate
metabolic syndrome
physical activity
insulin resistance
drug induced
open label